Magnetar Financial LLC Acquires 21,607 Shares of Charles River Laboratories International, Inc. $CRL

Magnetar Financial LLC boosted its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 1,379.8% during the third quarter, HoldingsChannel.com reports. The fund owned 23,173 shares of the medical research company’s stock after purchasing an additional 21,607 shares during the period. Magnetar Financial LLC’s holdings in Charles River Laboratories International were worth $3,626,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in CRL. Norges Bank acquired a new stake in Charles River Laboratories International during the second quarter valued at approximately $76,952,000. National Bank of Canada FI lifted its position in shares of Charles River Laboratories International by 1,179.5% during the 2nd quarter. National Bank of Canada FI now owns 434,868 shares of the medical research company’s stock worth $65,983,000 after buying an additional 400,881 shares during the period. Balyasny Asset Management L.P. boosted its stake in Charles River Laboratories International by 722.5% in the 2nd quarter. Balyasny Asset Management L.P. now owns 434,226 shares of the medical research company’s stock valued at $65,885,000 after buying an additional 381,432 shares in the last quarter. Ariel Investments LLC grew its position in Charles River Laboratories International by 28.6% in the second quarter. Ariel Investments LLC now owns 1,415,348 shares of the medical research company’s stock valued at $214,751,000 after acquiring an additional 314,572 shares during the period. Finally, LSV Asset Management raised its stake in Charles River Laboratories International by 1,773.0% during the third quarter. LSV Asset Management now owns 297,800 shares of the medical research company’s stock worth $46,594,000 after acquiring an additional 281,900 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on CRL shares. Barclays cut their price objective on Charles River Laboratories International from $215.00 to $200.00 and set an “overweight” rating for the company in a report on Thursday, February 19th. TD Cowen dropped their target price on shares of Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, February 20th. Robert W. Baird set a $193.00 price target on shares of Charles River Laboratories International in a report on Thursday, February 19th. Wall Street Zen lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Finally, Morgan Stanley set a $185.00 price objective on shares of Charles River Laboratories International in a research note on Monday, December 1st. Ten investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Charles River Laboratories International currently has an average rating of “Moderate Buy” and a consensus price target of $203.57.

Charles River Laboratories International Price Performance

Shares of CRL stock opened at $168.88 on Thursday. Charles River Laboratories International, Inc. has a 52 week low of $91.86 and a 52 week high of $228.88. The stock has a market capitalization of $8.31 billion, a PE ratio of -57.05, a PEG ratio of 2.86 and a beta of 1.64. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.02 and a current ratio of 1.29. The stock’s fifty day moving average is $193.48 and its 200-day moving average is $181.14.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, February 18th. The medical research company reported $2.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.33 by $0.06. The business had revenue of $994.23 million during the quarter, compared to analysts’ expectations of $986.98 million. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The firm’s revenue for the quarter was down .8% compared to the same quarter last year. During the same period in the previous year, the business posted $2.66 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. Equities research analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.